Applied DNA Sciences Stock Scheduled to Reverse Split on Thursday, April 25th (NASDAQ:APDN)

Applied DNA Sciences, Inc. (NASDAQ:APDN)’s stock is scheduled to reverse split on the morning of Thursday, April 25th. The 1-20 reverse split was announced on Thursday, April 25th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, April 25th.

Applied DNA Sciences Trading Down 12.1 %

Shares of NASDAQ APDN traded down $0.04 during trading on Tuesday, reaching $0.29. 811,420 shares of the company traded hands, compared to its average volume of 116,854. The firm’s fifty day simple moving average is $0.49 and its 200 day simple moving average is $0.67. The stock has a market cap of $4.92 million, a P/E ratio of -0.54 and a beta of 0.07. Applied DNA Sciences has a 12-month low of $0.28 and a 12-month high of $1.86.

Applied DNA Sciences (NASDAQ:APDN) last announced its quarterly earnings results on Thursday, February 8th. The technology company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.22. Applied DNA Sciences had a negative return on equity of 159.93% and a negative net margin of 80.14%. The firm had revenue of $0.89 million during the quarter, compared to analyst estimates of $0.70 million. As a group, research analysts expect that Applied DNA Sciences will post -0.63 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on APDN shares. StockNews.com started coverage on shares of Applied DNA Sciences in a research note on Sunday. They set a “hold” rating for the company. HC Wainwright lowered their target price on shares of Applied DNA Sciences from $2.00 to $1.50 and set a “buy” rating for the company in a research note on Friday, February 9th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Applied DNA Sciences stock. Silverberg Bernstein Capital Management LLC purchased a new stake in Applied DNA Sciences, Inc. (NASDAQ:APDN) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 98,301 shares of the technology company’s stock, valued at approximately $61,000. Silverberg Bernstein Capital Management LLC owned about 0.72% of Applied DNA Sciences as of its most recent SEC filing. 22.22% of the stock is currently owned by institutional investors.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.